Public Citizen Wants Serzone Pulled; No “Unique” Benefit To Offset Risk

Bristol-Myers Squibb's Serzone offers "no unique therapeutic benefit" to justify continued marketing in light of liver toxicity concerns, Public Citizen maintains in a March 6 petition to FDA